A Randomised, Open, Two-Way Cross-Over, Phase I Study to Evaluate the Response to Glucagon Versus the Spontaneous Counter-Regulatory Response in T2DM Patients Treated With AZD1656 and Metformin During Hypoglycemia.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2014
At a glance
- Drugs AZD 1656 (Primary) ; Glucagon
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 08 May 2009 Additional location Sweden identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History